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Background: The development of classification methods for personalized
medicine is highly dependent on the identification of predictive genetic mark-
ers. In survival analysis, it is often necessary to discriminate between influential
and noninfluential markers. It is common to perform univariate screening using
Cox scores, which quantify the associations between survival and each of the
markers to provide a ranking. Since Cox scores do not account for dependencies
between themarkers, their use is suboptimal in the presence of highly correlated
markers.
Methods: As an alternative to the Cox score, we propose the
correlation-adjusted regression survival (CARS) score for right-censored
survival outcomes. By removing the correlations between the markers, the
CARS score quantifies the associations between the outcome and the set of
“decorrelated” marker values. Estimation of the scores is based on inverse
probability weighting, which is applied to log-transformed event times. For
high-dimensional data, estimation is based on shrinkage techniques.
Results: The consistency of the CARS score is proven under mild regularity
conditions. In simulations with high correlations, survival models based on
CARS score rankings achieved higher areas under the precision-recall curve
than competing methods. Two example applications on prostate and breast can-
cer confirmed these results. CARS scores are implemented in the R package
carSurv.
Conclusions: In research applications involving high-dimensional genetic data,
the use of CARS scores for marker selection is a favorable alternative to Cox
scores even when correlations between covariates are low. Having a straightfor-
ward interpretation and low computational requirements, CARS scores are an
easy-to-use screening tool in personalized medicine research.
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1 INTRODUCTION
One of the key issues in personalizedmedicine is to identify genetic marker signatures for the planning and the prognosis
of targeted cancer therapies. With more than one of three people developing some form of cancer during their lifetimes,1
individualized therapies based on genetic markers are expected to play a major role in improving progression-free and
overall survival of cancer patients. Among men, for example, prostate cancer is the cancer with the highest prevalence.
While there are several clinical models available for predicting disease progression, it remains a challenging task to
develop molecular signatures and improve predictive accuracy of existing models.2
Since cancer research is heavily focused on time-to-event outcomes such as progression-free survival, metastasis-free
survival, and/or overall survival, survival analysis is one of the predominant statistical approaches to analyze data col-
lected in clinical cancer trials. When the aim is to relate a time-to-event outcome to a set of predictors (eg, clinical
information or genetic markers), it is common to use a survival model such as the proportional hazards model by Cox.3
However, when data are high dimensional (eg, when the number of measured genetic markers exceeds the sample size),
it is impossible to fit a Cox regression model including all available covariates. A solution to this problem could be to use
regularized methods such as ridge-penalized Cox regression, but even these methods often break down when the num-
ber of available markers (in particular, the number of noninfluential markers) is large. It is therefore common practice to
carry out data-driven variable selection before fitting the survival model and to include only those “influential markers”
that have passed the selection step.
The predominant method for variable selection in cancer research is univariate screening, which evaluates the asso-
ciations between the outcome of a trial and each covariate separately, eg, by computing correlation coefficients or
fitting simple regression models. The coefficients of association are usually ranked by magnitude, and the most highly
ranked covariates are selected for inclusion in the statistical model of interest. Fan and Lv4 have provided a theoreti-
cal justification for this approach by showing that univariate screening is suitable for identifying influential covariates
with high probabilities under mild regularity conditions. Still, a major problem of this approach is that associa-
tions between covariates are ignored. For example, the set of selected markers may include so-called “antagonistic”
variables that are highly correlated among each other but whose correlation/regression coefficients have opposing
signs. While decreasing the robustness of the final statistical model, such marker variables will also cause influen-
tial markers with weaker univariate associations to be dropped from the model. This information loss is particularly
problematic when the number of selected markers needs to be restricted to a small value due to sample size or cost
limitations.
In survival analysis with a right-censored time-to-event outcome, univariate screening is mostly done by computing
Cox scores, which are given by either the Z scores obtained from univariate Cox regression models or by the p values
obtained from the respective likelihood ratio or score tests. Although p values can be corrected for multiple testing (eg,
see the work of Benjamini and Hochberg5) to identify informative covariates, Cox scores share the same disadvantages as
the univariate screening methods mentioned above.
To address these problems, we consider the correlation-adjusted regression (CAR) score approach, which provides
a criterion for variable ranking that is based on the decorrelation of covariates in linear regression. By applying a
Mahalanobis-type “decorrelating” transformation to the covariates, CAR scores measure the correlations between the
decorrelated variables and the continuous outcome. The set of correlation coefficients defines a ranking of the covariates,
which can be used to select informative variables in the same way as with the univariate screening methods described
above. As the correlation coefficients among the covariates tend to zero, CAR scores become identical to the correlations
between the nontransformed covariates and the outcome. In simulations for linear regression, CAR scores outperformed
methods for regularized regression (boosting, lasso) with regard to their ability to correctly recover causal genetic mark-
ers and their rankings.6 On the other hand, CAR scores have not been used to model time-to-event outcomes in cancer
research, as an extension of the CAR approach to right-censored data has been lacking so far.
The purpose of this paper is therefore to develop a CAR-based method for ranking high-dimensional sets of genetic
marker variables in survival analysis. The resulting score, which, in the following, will be termed correlation-adjusted
regression survival (CARS) score, quantifies the correlations between the log-transformed survival time Y = log(T)
and the decorrelated set of covariates X. We will first define a theoretical version of the CARS score on the pop-
ulation level (Section 2.1). Afterward, we will provide details on the estimation of the scores from a sample of
right-censored data (Section 2.2). Specifically, we will show that all relevant expressions can be estimated using
inverse-probability-of-censoring (IPC) weighting techniques, as proposed by Van der Laan and Robins.7 In Section 3, we
will present the results of a simulation study that was carried out to compare the CARS approach to univariate screening
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based on Cox scores. In addition, we will apply CARS scores to the Swedish Watchful Waiting Cohort data2 and to a data
set on invasive breast cancer.8 The results of the paper will be summarized in Section 4.
2 METHODS
2.1 Full data world/population level
The main focus of survival modeling is on analyzing the effects of a set of covariates x ∈ ℝd on a survival time T ∈ ℝ+.
We assume that the vector x = (X1, … ,Xd)⊤ has expectation 𝝁, covariance matrix 𝚺, and correlationmatrix PX. Similarly,
we assume that the survival time T has a finite expectation 𝜇T and variance 𝜎2T . A popular approach to quantify the
relationship between T and x is the parametric accelerated failure time (AFT) model,9 which is based on log-transformed
survival time Y ∶= log(T) and the model equation
Y = 𝛽0 + xT𝜷 + 𝜖, (1)
where 𝜷 ∈ ℝd is a vector of regression coefficients and 𝜖 is a noise variable. For the derivation of CARS scores, we
will consider the special case of lognormally distributed survival times, ie, 𝜖 is assumed to follow a normal distribution
with zero mean and constant variance. Then, the expected squared prediction error E ((Y − 𝛽0 − xT𝜷)2) is minimized by
regression coefficients equal to
𝜷∗ = Σ−1ΣXY , (2)
where ΣXY is the d-dimensional vector of covariances between x and Y, and the intercept
𝛽∗0 = 𝜇Y − 𝜷
T𝝁. (3)
Equation (1) is a Gaussian linear regression model. Therefore, in the absence of censoring, a measure of variable
importance is the CAR score 𝜽10 defined by
𝜽 = P−1∕2X PX ,Y , (4)
where PX ∈ ℝd×d is the correlation matrix of the covariates x and PX ,Y ∈ ℝd×1 is the vector of correlations between the
covariates x and the log-transformed survival time Y = log(T). Analogous to Cox scores, the components of 𝜽 can be
ordered by magnitude to give an importance ranking of the covariates.
The original CAR score for Gaussian linear regression can be interpreted as the correlations between the outcome
variable and the decorrelated covariates, which are defined by the orthogonal transformation z = P−1∕2X x.10 Using the best
linear unbiased predictor Y⋆ = 𝛽∗0 + xT𝜷
∗ derived from the estimators (2) and (3) and defining 𝜎2Y ∶= Var(Y ), the total
variance of Y can be decomposed as follows:
Total variance
⏞ ⏞
Var(Y ) =
Explained variance
⏞⏞ ⏞
Var(Y⋆) +
Unexplained variance
⏞⏞⏞⏞⏞⏞ ⏞⏞⏞⏞⏞
Var(Y − Y⋆) (5)
= 𝜎2YP2Y ,Y∗ + 𝜎2Y
(
1 − P2Y ,Y∗
)
, (6)
where
P2Y ,Y∗ = P⊤X ,YP−1X PX ,Y = 𝜽
T𝜽 (7)
is the squared correlation betweenY andY ∗. FromEquations (5) to (7), it follows that the CAR score is the central quantity
to assess which variables contribute to the explained variance, or equivalently reduce the unexplained variance. Impor-
tantly, P−1∕2X x is not the Mahalanobis transform but another form of decorrelation that has the advantageous feature of
maximizing the correlation between the decorrelated covariates and the standardized original covariates.11 In contrast,
the Mahalanobis transform maximizes the cross-covariance between the decorrelated covariates and the original covari-
ates. Zuber et al6,10 demonstrated that the estimatedCAR scores result in improved variable rankings and higher predictive
performance when compared to other variable selection and modeling techniques, such as lasso or boosting.
Similar to the Elastic Net,12 variable selection using the CAR score exhibits the grouping property,10 which ensures that
highly correlated nonantagonistic variables receive similar CAR scores and are thus close. This property is often desirable
from an explanatory modeling perspective.12 The grouping property also implies that CAR scores typically do not select a
“prototype” out of a group of highly correlated variables, where prototype variable selection may be potentially useful for
predictionmodeling in some scenarios. Another favorable property of CAR scores is that antagonistic positively correlated
variables tend to be bottom ranked and that null predictors (showing no correlation with the response) will be identified
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(ie, bottom ranked) with probability 1 as long as the employed estimator is consistent. For details on the properties of
CAR scores, see the work of Zuber and Strimmer.10
Although these estimated scores work well for regression models with a continuous outcome, they were not able to
deal with right-censored data so far. We will therefore develop the CARS score that extends traditional estimators of CAR
scores to survival modeling.
2.2 Observed data world/sample level
In the observed data world, one often has to deal with right-censoring, ie, one is no longer able to observe the uncensored
survival times of all observations but only the minimum of the true survival time T and a censoring time C ∈ ℝ+. The
observed variable of interest is then defined by Ỹ = log(T̃), where T̃ ∶= min(T,C). Additionally, we introduce a status
indicator Δ ∶= I(T ≤ C ), ie, Δ = 1 if the event is observed and Δ = 0 if censoring has occurred. We will further
assume that T and C are independent random variables conditional on the covariates x (“noninformative censoring”). At
the sample level, the empirical CAR score is defined by
?̂? = R−1∕2shrinkRX ,Y , (8)
where Rshrink ∈ ℝd×d is a shrinkage estimator of the correlation matrix PX and RX ,Y ∈ ℝd×1 is an estimator of the vector
of correlations PX,Y.10 The definition of Rshrink will be provided below. In contrast to uncensored Gaussian regression,
the standard estimation of PX,Y using the sample correlations between x and Ỹ is no longer appropriate, as this would
result in biased estimators in the presence of right-censoring. To overcome this problem, we suggest adjusting the sample
correlations by IPC weighting,7 which will result in a consistent estimator of PX,Y.
Definition of IPC weights for right-censored data: Let T̃1, … , T̃n be the observed values of T̃ and C1, … ,Cn be the
underlying censoring times in a sample of independent and identically distributed observations of size n. Following the
work of Van der Laan and Robins,7 we define the IPC weight of the ith observation by
wi ∶=
Δi
Ĝn(log(T̃i))
, i ∈ {1, … ,n}, (9)
where Δi, i = 1, … ,n, are the sample values of Δ and Ĝn(·) is an estimate of the survival function G(·) of the logarithmic
censoring process, ie, the probability
G(𝑦) = P(log(C) > 𝑦). (10)
By definition, censored observations (Δi = 0) result in zero IPC weights. In line with the work of Van der Laan and
Robins,7 we further assume that G(·) > 𝜈 > 0, where 𝜈 is a small positive real number (this assumption will become
important in the consistency proof in Supplementary Appendix A1). To compute Ĝn(·), we apply the Kaplan-Meier
estimator to the observed logarithmic survival times T̃1, … , T̃n, using the event indicators 1 − Δi, i = 1, … ,n.
Remark. The definition of the IPC weights in (9) can be extended by allowing the censoring survival function G to
conditionally depend on the covariates. For this, it needs to be assumed that Ĝn(log(T̃)|x) is a consistent estimator
of the true conditional censoring distribution G(log(T̃)|x). In practice, Ĝn(log(T̃)|x) is usually obtained by fitting a
multivariable time-to-event model to the observed survival times with event indicator 1 − Δ. If the latter model is
specified correctly, the following results on the consistency of ?̂? will also hold if G depends on x. For details, see
Supplementary Appendix A.
Estimation of the correlation vector PX,Y using IPC weighting: The estimation of PX,Y comprises the following steps.
1. Estimate the expectations of the covariates X1, … ,Xd by their empirical means X̄𝑗 =
∑n
i=1 Xi 𝑗∕n, j = 1, … , d, where
Xi j denotes the sample value of the jth covariate in observation i. Similarly, estimate the variances of X1, … ,Xd by
their sample variances S2𝑗 =
∑n
i=1 (Xi 𝑗 − X̄𝑗)2∕(n − 1), j = 1, … , d.
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2. Estimate the expectation of Y by the weighted mean
Ȳw =
1
n
n∑
i=1
wi log(T̃i) , (11)
where wi, i = 1, … ,n, are the IPC weights defined in Equation (9). Similarly, estimate the variance of Y by
S2Y ;w =
1
n
n∑
i=1
wi
(
log(T̃i) − Ȳw
)2
. (12)
3. The covariance of Xj and Y is again estimated using IPC weighting, ie,
SX𝑗 ,Y ;w =
1
n
n∑
i=1
wi(Xi 𝑗 − X̄𝑗)
(
log(T̃i) − Ȳw
)
, 𝑗 = 1, … , d. (13)
4. The final step is to compute the empirical correlation vector RX,Y by combining the estimators defined in Steps 1 to 3
above, as follows:
RX ,Y =
⎛⎜⎜⎜⎝
SX𝑗 ,Y ;w√
S2X𝑗
√
S2Y ;w
⎞⎟⎟⎟⎠𝑗=1,… ,d
. (14)
Estimation of the correlation matrix P−1∕2X : Since the data values of the covariates are not affected by censoring,
the usual sample variance-covariance estimators could be applied to obtain an estimate of P−1∕2X . In the presence of
high-dimensional data, however, these estimators usually break down. For example, the estimation of the d × d correla-
tionmatrixPX—or,more precisely, its inverse square root—is challenging when d is much larger than the sample size.13,14
We therefore propose to employ a shrinkage correlation estimator,10,15 to estimate PX, which is given by
Rshrink = 𝜆Id + (1 − 𝜆)RX , (15)
where 𝜆 ∈ ℝ+ is a shrinkage parameter, Id is the identity matrix of dimension d × d, and RX is the matrix containing the
empirical bivariate sample correlations of the covariates. Following the approach in the work of Schäfer and Strimmer,15
we define 𝜆 ∶= ∑𝑗≠kV̂ar(r𝑗,k)∕∑𝑗≠kr2𝑗,k, where rj, k denotes the sample correlation between the jth and the kth covariate.
The inverse square root R−1∕2shrink can be computed very efficiently by applying singular value decomposition of the sample
correlation matrix. For details, we refer to the works of Zuber and Strimmer10 and Kessy et al.11 The estimation of PX,Y
described above, combined with the shrinkage estimator Rshrink, defines the CARS score in Equation (8).
Consistency of CARS scores: Next, we give a sketch of the consistency proof for the estimated CARS score ?̂? =
R−1∕2shrinkRX ,Y . As shown in detail in Supplementary Appendix A.4, ?̂? converges to its population value 𝜽 = P
−1∕2
X PX ,Y as
n → ∞, provided that (i) censoring is independent of the survival times conditional on x and (ii) the estimator Ĝn is a
consistent estimator of the censoring survival function G. More specifically, by embedding the IPC-weighted expressions
given in the estimators (11) to (14) in the framework of unbiased estimating equations,16,17 we show that each of the esti-
mators contained in the definition of ?̂? is a consistent estimator of its respective population variance or covariance. As a
consequence, ?̂? results in a consistent estimator of the population value 𝜽.
Variable selection based on CARS scores: As shown above, CARS scores measure the associations between the decor-
related covariates and the time-to-event outcome T. Variable selection can therefore be carried out by ranking the CARS
scores according to their absolute values. A set of covariates is selected whose absolute CARS scores exceed the prede-
fined threshold value 𝜙. A suitable threshold can, for example, be obtained by cross-validating the multivariable survival
model that incorporates the selected covariates. In this paper, we will use a computationally less expensive strategy and
apply the adaptive false discovery rate density approach proposed by Strimmer,18 which assumes a two-component dis-
cretemixturemodel of “influential” and “noninfluential” covariates. On the basis of thismodel, a suitable threshold value
𝜙 can be estimated by a trade-off between the false-nondiscovery rate P(“influential”|𝜃 ≤ 𝜙) and the false-discovery rate
P(“not-influential”|𝜃 ≥ 𝜙). The associated parameters of the mixture model are estimated by penalized maximum like-
lihood and a modified semiparametric Grenander estimator.18,19 For details and for an overview of the advantages of the
approach, we refer to the work of Strimmer.18
Note that in the derivation of the CARS estimator ?̂?, we implicitly assumed that there are no missing values in the
data, as pairwise correlations cannot be computed when there are missing values in at least one of the variables. We note
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that our estimation approach may easily be combined with state-of-the-art methods for dealing with missing covariate
values, for example, with multiple imputation20 under the missing-at-random assumption. After imputation, the CARS
estimation approach may be applied to each imputed data set as described above.
3 RESULTS
3.1 Design of the simulation study
To analyze the performance of CARS scores, we compared the CARS-based screening approach to a univariate screening
approach using Cox scores.4 With the latter approach, a univariate Cox model was fitted for each covariate, and the Cox
scores were given by the standardized coefficients of these models. In addition, we fitted multivariable Cox regression
models with L1-penalized coefficient estimates.21 In thesemodels, a variable was considered to be “included” in themodel
when its L1-penalized coefficient estimate differed from zero. To ensure a fair comparison with the other methods, no
tuning of the regularization parameter was applied in the main simulation study, as this would have required additional
test data. Instead, we used the median value of the default L1-norm regularization path computed by the R22 package
glmnet.21 Furthermore, we carried out an additional simulation study that investigated the impact of tuningmultivariable
L1-penalized Cox regression models using 10-fold cross-validation (see Section 3.5).
We considered three sample sizes (n ∈ {250, 500, 1000}) and three dimensions of the covariate space (d ∈
{500, 1000, 2000}). The covariate values were generated from a multivariate normal distribution with zero mean. For the
covariance structure of the multivariate normal distribution, a block correlation structure with three equally sized blocks
was constructed. In the first block, 50% of the correlations were set to 𝜌 = −0.25, and the other 50%were set to 𝜌 = 0.25.
In the second block, 50% of the correlations were set to 𝜌 = 0.5, and the other 50% were set to 𝜌 = −0.5. In the third
block, 50% of the correlations were set to 𝜌 = 0.75, and the other 50% were set to 𝜌 = −0.75. The correlation between
covariates belonging to different blocks was zero. To satisfy the restrictions of a correlation matrix (eg, positive definite-
ness), the closest correlation matrix with regard to quadratic element-wise differences was computed. Further details on
the algorithm for the construction of the correlation matrix are given in Supplementary Appendix B.7.
The percentages of influential covariates that were related to the time-to-event outcome was varied according to the
values of 1%, 5%, and 10%. Two different correlation scenarios were analyzed: in the first scenario, all influential vari-
ables were taken from the first block of the correlation matrix (“scenario with low absolute correlations”); in the second
scenario, all influential variables were taken from the third block (“scenario with high absolute correlations”). The sur-
vival process was assumed to follow a lognormal distribution T ∼ logN(log𝜇T , log 𝜎2T) with expectation log𝜇T = X𝜷.
The coefficients 𝜷 were specified to be equidistant within the interval [−0.9, 1], depending on the number of influential
covariates. The variance log 𝜎2T was adjusted such that explained variances of {25%, 50%, 75%} were achieved on the log
scale. In another scenario (Section 3.5), Weibull-distributed survival times T ∼ W(Φ = exp(X𝜷), 𝜑), with scale Φ and
shape 𝜑, were explored. In this scenario, the parameter 𝜑 was determined by prior simulations with a large data set of
106 observations to achieve a predefined variance, which was determined by a signal-to-noise ratio of 0.5. The Weibull
scenario was considered because this distribution guarantees that the assumptions of both the AFT model and the Cox
model are satisfied at the same time, so that CARS scores and Cox scores were more directly comparable than in the log-
normal scenario. The censoring process was assumed to be lognormally distributed. Its parameters were adjusted such
that censoring rates of 0.25 and 0.75 were obtained. To emulate administrative censoring, all values of the survival times
that were higher than the 90% quantile of the distribution of T were cut off and set to be censored. The 90% quantile was
determined by prior simulations with a large sample size of 106 observations for each scenario and remained fixed during
simulations. For each of the scenarios, we carried out 300 independent simulation runs.
To evaluate the performance of the methods, the covariates selected by CARS scores, Cox scores, and L1-penalized Cox
regression were compared to the sets of influential variables having a true (nonzero) effect on the survival times. For each
threshold of the CARS and Cox scores, these comparisons resulted in the cross-tabulation of the binary variables “selected
vs nonselected” and “influential vs noninfluential.” In the case of L1-penalized Cox regression, variables with coefficients
different from zero were defined as selected and all other variables as nonselected. Since we were interested in detecting a
small set of influential markers within a sparse modeling framework, we used the area under the precision-recall curve23
to evaluate the cross tables and to measure the performance of the three methods. In addition, we investigated the ability
of the methods to rank the variables—from least to most important—by analyzing the rank correlations between the true
absolute coefficients and the corresponding estimated absolute CARS or Cox scores.
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FIGURE 1 Results of the simulation study. PR-AUC of CARS, Cox, and Cox L1 scores stratified by sample size (n) and number of
covariates (d) with low absolute covariate correlations (𝜌 = ±0.25) and low censoring rate of 25%. Each boxplot summarizes the results of
2700 simulation runs (3 explained variance ratios × 3 signal-to-noise ratios × 300 repetitions)
3.2 Scenario with low absolute correlations and low censoring rate
We first present the results of the scenario with low absolute correlations (first block of the correlation matrix, 𝜌 =
±0.25) and 25% censoring rate. After running the algorithm for the construction of the correlation matrix (presented
in Supplementary Appendix B.7), all correlations had absolute values that were smaller than 0.3. Figure 1 shows the
summary of all simulation results stratified by sample size n and number of covariates d. The median PR-AUC of the
CARS score approach was higher than the respective median PR-AUC values obtained from Cox scores and L1-penalized
Cox regression for all combinations of n and d. In addition, Figure B1 in Supplementary Appendix B.1 displays the results
with respect to the relative number of influential variables (relVar) and the explained variance (expVar). In most cases,
CARS scores had a clearly higher median PR-AUC performance than the other approaches, except for the cases where
relVar = 0.01 with expVar = 0.5 or expVar = 0.75 and relVar = 0.05 with expVar = 0.75. In these cases, the median
PR-AUC values of CARS and L1-penalized Cox regression were more similar, but CARS scores still outperformed Cox
scores. Higher signal-to-noise ratios increased the performance of CARS scores on average. The PR-AUC of CARS scores
had a larger variability compared to the Cox-based approaches, where L1-penalized Cox scores showed a larger variability
in PR-AUC than Cox scores. Further CARS scores ranked influential variables better in the median than Cox scores, as
shown in Figure B2 in the Supplementary Appendix. An overall nonstratified summary is available in Supplementary
Appendix B.1 (Figure B3).
3.3 Scenario with high absolute correlations and low censoring rate
Figure 2 presents the results of the scenario with high absolute correlations (third block of the correlation matrix,
𝜌 = ±0.75) and with a censoring rate of 25%. The median PR-AUC of the CARS scores was higher than for both
Cox-based approaches for most combinations of n and d. Of note, the PR-AUC performance of Cox scores decreased
stronger than the PR-AUC performance of CARS scores in comparison to the low-correlation scenario with 𝜌 = 0.25.
Figure B4 in Supplementary Appendix B.2 displays the results with respect to the number of influential variables and the
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FIGURE 2 Results of the simulation study. PR-AUC of CARS, Cox, and Cox L1 scores stratified by sample size (n) and number of
covariates (d) with high absolute covariate correlations 𝜌 = ±0.75 and censoring rate of 25%. Each boxplot shows the results of 2700
simulation runs (3 explained variance ratios × 3 signal-to-noise ratios × 300 repetitions)
explained variances. If relVar > 0.05, CARS scores had again higher median PR-AUC performance than both Cox-based
approaches. The lack of adjustment for between-covariate correlations obviously degraded the performance of Cox scores.
A similar effect was seen in the rank correlations (Figure B5 in the Supplementary Appendix); in particular, the gap
betweenmedian rank correlations of CARS and Cox scores became somewhat larger compared to the low-correlation sce-
nario (Figure B2 in the Supplementary Appendix). Figure B6 shows an overall nonstratified summary of the simulation
results (Supplementary Appendix B.2).
3.4 Scenario with high absolute correlations and high censoring rate
Next, we analyzed the results of the scenario with high absolute correlations (third block of the correlation matrix,
𝜌 = ±0.75) and with a high censoring rate of 75%. This case is particularly challenging, as approximately 75% of the IPC
weights became zero, implying that CARS scores were essentially computed from only 25% of the observations. Consider,
for example, the cases n <= d in Figure 3, where the PR-AUC performance of all methods was nearly random. If the sam-
ple size increased above the number of covariates (ie, n > d), the median PR-AUC performance of CARS scores became
better than the respective performance of the Cox-based approaches. Increasing the number of influential covariates from
relVaR = 0.01 to relVar = 0.1 improved the PR-AUC performance of the CARS score approach. Particularly in the cases
with relVar = 0.1 and explained variance expVar >= 0.5, CARS scores achieved better results in the median than the
Cox-based approaches (see Figure B7 in Supplementary Appendix B.3). Regarding the rank correlations, the CARS score
approach behaved better than the Cox score approach (Figure B8 in Supplementary Appendix B.3), although the differ-
ences between the approaches were less pronounced than in the previous scenario with high correlations of 𝜌 = ±0.75
and low censoring rate of 25%. As in the previous scenarios, Cox scores showed, by far, the worst performance among the
three methods on average. Figure B9 shows an overall nonstratified summary of the simulation results (Supplementary
Appendix B.3).
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FIGURE 3 Results of the simulation study. PR-AUC of all methods stratified by sample size (n) and number of covariates (d) with high
absolute covariate correlations of 𝜌 = ±0.75 and censoring rate of 75%. Each boxplot shows the results of 2700 simulation runs (3 explained
variance ratios × 3 signal-to-noise ratios × 300 repetitions)
3.5 Scenario withWeibull-distributed survival times and low absolute correlations
Here,we present the results of the scenariowith lowabsolute correlations (first block of the correlationmatrix, 𝜌 = ±0.25)
and with 25% censoring rate. In contrast to Section 3.2, the survival times were generated from a Weibull distribution
with a logarithmic link function, and the signal-to-noise ratio was fixed to 0.5. Moreover, L1-penalized Cox regression was
additionally tuned by cross-validation. Figure B10 in Supplementary Appendix B.3 shows the summary of all simulation
results. The performance of CARS scores relative to Cox scores and untuned L1-penalized Cox regression was essentially
comparable to its respective performance in the lognormal scenario, with the CARS score approach performing best in a
number of cases. For example, in the cases with n = 250 and d = 2000, the median CARS PR-AUC performance was
distinctly better than the respective performance of the other methods. Still, the performance of untuned L1-penalized
Cox regression notably improved (possibly due to the true data-generating Weibull model being a Cox regression model),
with L1-penalized Cox regression tending to perform even better in the median—albeit showing a larger variance—than
CARS scores when the number of observations increased (n = 1000). A comparison of untuned and tuned L1-penalized
Cox regression shows that the tunedmodels performed better than the untunedmodels in the large-sample-size scenarios.
Of note, the CARS scores outperformed both the tuned and untuned L1-penalized Cox models in the higher-dimensional
scenarios (n ≤ 500, d = 2000).
Figure B11 in the Supplementary Appendix displays the results with respect to the relative number of influential
variables (relVar) and the explained variance (expVar). All methods degraded in performance when the number of
equicorrelated influential variables (and, thus, multicollinearity) increased, especially the Cox scores. Furthermore,
L1-penalized Cox regression showed an increased variance, whereas the behavior of the CARS scores was more robust.
Again, CARS scores ranked influential variables better in the median than Cox scores, as shown in Figure B12 in the
Supplementary Appendix. An overall nonstratified summary is available in Supplementary Appendix B.3 (Figure B13),
confirming that tuned L1-penalized regression performed slightly better with respect to PR-AUC than CARS scores in the
median but showed a larger variance.
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3.6 Scenario withWeibull-distributed survival times and high absolute correlations
Figure B14 in Supplementary Appendix B.3 presents the results of the scenario with high absolute correlations (third
block of the correlation matrix, 𝜌 = ±0.75) and with a censoring rate of 25%. Overall, the conclusion is similar as in the
scenario with lognormal distribution (Section 3.3). The median PR-AUC of the CARS score approach was throughout
higher than the respective median PR-AUC values of the two Cox-based approaches for all combinations of n and d.
The PR-AUC performance of the Cox approaches decreased in comparison to the low-correlation 𝜌 = 0.25 scenario. In
contrast to the latter scenario, the untuned L1-penalized models performed better throughout than the respective tuned
models. Figure B15 in the SupplementaryAppendix displays the results with respect to the number of influential variables
and the explained variances. For relVar >= 0.05, CARS scores had a distinctly highermedian PR-AUC performance than
all other methods. Obviously, the lack of adjustment for between-covariate correlations again degraded the performance
of Cox scores. A similar effect was seen in the rank correlations (Figure B16 in the Supplementary Appendix). Figure B14
shows an overall nonstratified summary of the simulation results (Supplementary Appendix B.3).
3.7 Runtime in the low-correlation, low-censoring scenario
The applicability of CARS scores to high-dimensional genomic data is determined not only by predictive performance but
also by the computational efficiency ofCARS score estimation. To analyze the latter,we additionally recorded the runtimes
of CARS score, Cox score, and L1-penalized Cox estimation without threshold models in the baseline scenario with low
covariate correlations 𝜌 = ±0.25 and low censoring rate 0.25. All runtimes were recorded using the R statistical software
without parallelization on the same computer with an Intel Core i7-7700 CPU at 4.20 GHz and 16-GB RAM. CARS scores
were computed by using the R package carSurv. Cox scores were calculated using the R packages survival and glmnet.
Figure B18 in Supplementary Appendix B.6 shows that in the scenarios with n = 500, the average computational time
of CARS scores was, in comparison to Cox scores (without the L1 penalty), about twice as fast to compute. Particularly
in the high-dimensional context with n = 250, the average runtimes of the CARS scores were about seven times faster
compared to the average Cox score runtimes. In the scenario with n = 1000 and d = 500, CARS and Cox approaches
yielded comparable runtimes, and in the scenarios with n = 1000 and d > 500, the Cox approaches performed faster.
3.8 Application to the SwedishWatchful Waiting Cohort
To investigate the properties of the proposed screening method in a real-world setting, we applied the CARS score
approach to the SwedishWatchful Waiting Cohort data.2 The publicly available data consist of 281 patients and 6157 vari-
ables that did not contain any missing values. Apart from the clinical covariates (such as patient age, Gleason score, and
year of diagnosis), an array of 6100 gene expression profiles (6K DASL) was designed by using four complementary DNA
(cDNA)-mediated annealing, selection, ligation, and extension (DASL) assay panels (DAPs).24,25 Further details of this
procedure are available at GeneExpression Omnibus (GEO: http://www.ncbi.nlm.nih.gov/geo/) with platform accession
number GPL5474. The data are also available at the GEO website with accession number GSE16560.
The study population included men who died from prostate cancer during follow-up or survived at least 10 years after
their diagnosis. The sample size was further restricted to men with high-density tumor regions and who did not receive
any type of androgen deprivation. The event of interest was death of prostate cancer; 26.69% of the patients were censored.
The median observed time was 100 months (range = [6, 274] months). The median age was 74 years (range = [51, 91]
years), the median Gleason score was seven (range = [2, 10]), and 58.72% of the patients had lethal diagnosis. The 2.5%
and 97.5% quantiles of the Pearson correlations between the gene expressions were [−0.2634, 0.2865], and the maximum
absolute correlation was 0.9861. We applied CARS scores to screen for genes that influenced time to death from prostate
cancer and evaluated their performance in comparison to Cox scores.
As the true effects of the genetic markers were unknown, it was not possible to analyze CARS and Cox scores by using
the PR-AUC and rank correlation techniques considered in the previous subsections. Instead, we evaluated the scores
by comparing their 10-times-repeated 10-fold cross-validated predictive performance. The latter was measured by the
time-dependent PR-AUC,26 which is an extension of PR-AUC to censored data.7 The time-dependent PR-AUC can be
interpreted as the average positive predictive value over time. In addition, we computed a time-independent summary
performance measure by weighting and integrating PR-AUC over time. In each of the 10 × 10 training folds, CARS and
Cox scores were estimated. Each set of risk score values was split into influential and noninfluential genetic markers with
a predefined q value cutoff threshold 𝛼1 ∈ {0.01, 0.05, 0.1}. The cutoff threshold was compared to the q values given by
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FIGURE 4 Analysis of the Swedish Watchful Waiting Cohort. The boxplots show the integrated PR-AUCs of Cox models, as obtained from
10-times-repeated 10-fold cross-validation. In addition to the clinical baseline formula used in the work of Sboner et al,2 the models
contained genetic markers that were selected by CARS and Cox scores. The values {0.01, 0.05, 0.1} represent different q value thresholds. The
dashed line denotes the average time-integrated event rate and corresponds to the performance of a random classifier
themethod in the work of Strimmer18 described in Section 2. For the Cox scores, we used the same threshold procedure as
for the CARS scores. All genetic markers with lower q values than the specified threshold were selected and incorporated
into a multivariable Cox regression model that also included a clinical baseline formula with the variables age, Gleason
score, and extremity diagnosis (patient group lethal or indolent).2 The performance of a random classifier corresponds
to the time-integrated event rate, which was calculated as P(T < t0) averaged over all available time points t0 within
one-fold. The average of the time-integrated event rates was computed across the 10 × 10 cross-validation folds.
Time-integrated PR-AUCs for each fold are shown in Figure 4. All methods had higher integrated PR-AUC values than
a random classifier across all cross-validation folds. Genetic marker selection based on CARS scores resulted in a similar
predictive performance compared to genetic marker selection by Cox scores. Both approaches were fairly robust against
the choice of the threshold 𝛼1. According to Figure 4, there appears to be no predictive benefit when genetic markers are
added to the clinical baseline formula, with CARS scores and Cox scores producing consistent results. This agrees with
the findings in the original publication.2
The complete data analysis with univariate CARS score screening resulted in 0, 3, and 10 identified genetic markers
at the q value thresholds 𝛼1 = {0.01, 0.05, 0.1}, respectively (see Table C1 in the Supplementary Appendix). Genetic
marker selection by Cox scores yielded 1, 1, and 2 genetic markers at the same thresholds. Some of the selected genes by
CARS scores with 𝛼1 = 0.1match previous results from the literature: according to the NCBI database,27 the “BIRC5 bac-
uloviral IAP repeat containing 5” is an inhibitor of apoptosis and found in most tumor cells. The gene BMX nonreceptor
tyrosine kinase regulates differentiation and tumorigenicity of several types of cancer cells, and another gene (MLLT11,
transcription factor 7 cofactor) was expressed in several leukemic cell lines.
3.9 Application to breast cancer microarray data
In our second real-world example, we applied CARS and Cox scores to an invasive breast cancer data set collected by
Hatzis et al8 and Itoh et al.28 Merging both available microarray gene expression data sets in the NCBI database13 (GEO
accession numbers GSE25055, GSE25065, and GSE25066) resulted in 502 observations and 22 338 variables. The latter
consisted of 55 clinical and metadata variables and 22 283 gene expression markers. The gene expression data were col-
lected usingGPL96 [HG-U133A]AffymetrixHumanGenomeU133AArrays. Therewere two patientswithmissing values
that were excluded from statistical analysis. The outcome was the time to distant relapse-free survival before surgery
(median = 2.716 years, range = [0, 7.439] years); 21.91% of the patients had a relapse within the study duration. The 2.5%
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FIGURE 5 Analysis of the breast cancer data.8 The boxplots show the integrated PR-AUCs of L1-penalized Cox models, as obtained from
10-times-repeated 10-fold cross-validation. In addition to the clinical baseline formula, the models contained genetic markers that were
selected by CARS and Cox scores. The average time-integrated event rate is displayed as a dashed line, which corresponds to the performance
of a random classifier
and 97.5% quantiles of the Pearson correlations between the gene expressions were [−0.2467, 0.2725], and the maximum
absolute correlation was 0.9986.
Analogous to the previous subsection, we used 10-times-repeated 10-fold cross-validation to analyze predictive per-
formance. The clinical baseline model included the covariates age, tumor stage, and an indicator of estrogen receptor
(ER) positiveness. The genetic markers were selected by either CARS or Cox scores with different q value thresholds
𝛼1 = {0.01, 0.05, 0.1}. The significant genetic markers were added to the clinical covariates, and a multivariable Cox
regression model was fitted. Due to the large number of covariates, Cox regression was regularized with an additional L1
penalty. The regularization parameter was tuned by internal 10-fold cross-validation as implemented in the R package
glmnet.
The predictive performance of Cox regression based on CARS and Cox scores is shown in Figure 5. It is seen that
CARS scores performed better than Cox scores for all levels of 𝛼1. For example, when using 𝛼1 = 0.01 as the significance
threshold, 22 out of the 22 283 genetic markers were selected by the CARS-based procedure. Genetic marker selection
based on Cox scores identified zero genetic markers at 𝛼1 = 0.01 and failed to include influential genetic markers,
which degraded predictive performance. In contrast to the Swedish Watchful Waiting Cohort data, there were notable
improvements in predictive performance when the genetic markers were added to the clinical model. All identified genes
are presented in the Supplementary Appendix (Table C2).
In order to annotate the 22 genes indicated by the CARS score as highly associated with survival at a q value level
of 𝛼1 < 0.01, we conducted a gene set enrichment analysis based on gene ontology (GO)29 terms as implemented in
the Bioconductor30 package topGO.31 The GO framework provides a set of structured vocabularies for specific biologi-
cal domains that can be used to describe gene products in any organism. We computed Fisher's test for enrichment of
molecular function and report in Supplementary Table C3 the 32 GO terms that were enriched at the p value significance
level 𝛼2 < 0.05. Among the five GO terms that had attained 𝛼2 < 0.01 in the Fisher enrichment test, we detected both
protein-glycine ligase activity and protein-glycine ligase activity inhibition. Glycine metabolism has been associated with
cancer cell proliferation,32 and glycine uptake and catabolism can promote tumourigenesis and malignancy.33 The third
enriched GO term was Ras guanyl-nucleotide exchange factor activity. Guanyl-nucleotide exchange factors are proteins
that activate GTPases, which are enzymes binding and hydrolizing guanosine triphosphate. Ras is one of the key onco-
genes; althoughRasmutations are comparatively rare in breast cancer, theRasGAP (RasGTPaseActivating Proteins) gene
RASAL2 functions as a tumor suppressor.34 Furthermore, we found enrichment evidence for sodium bicarbonate sym-
porter activity, which enables the transfer of a solute or solutes from one side of amembrane to the other and has a central
role in pH regulation. Solid tumor exhibits different pH profiles compared to normal tissues, which points at a metabolic
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shift toward acid-producing pathways, reflecting both oncogenic signaling and the development of hypoxia.35 The sodium
bicarbonate cotransporter NBCn1 is the predominant mechanism of acid extrusion in primary breast carcinomas com-
pared to normal tissues affecting intracellular pH levels.36 Finally, we detected evidence of estrogen 16-alpha-hydroxylase
activity, which is one of the earliest reported biomarkers for breast cancer.37
4 SUMMARY AND DISCUSSION
With high-dimensional omics data becoming more readily available in medical research, fast and efficient screening
methods are needed for statistical model building and prediction. In this paper, we have developed a framework for the
selection of genetic markers in time-to-event models. This framework helps improve biomarker discovery especially in
high-dimensional settings with a large number of candidate variables. The proposed CARS score, which evaluates the
associations between the decorrelated marker values and the time-to-event outcome, is estimated consistently by com-
bining a set of IPC-weighted variance-covariance estimates. As shown in Section 2, estimates can be computed efficiently
even when the number of candidate markers is large. On the basis of the rankings of the CARS score estimates, genetic
markers can be selected for inclusion in a multivariable time-to-event model, where selection errors can be controlled by
the adaptive false discovery rate density approach.18
In the numerical experiments presented in Section 3, CARS scores showed promising results with regard to the iden-
tification of influential marker variables. In particular, screening based on CARS scores outperformed the traditional
screening methods based on Cox scores and showed a better performance than L1-penalized regression in many of the
analyzed scenarios (although not performing uniformly better, especially in scenarios where the proportional hazards
assumptionwas satisfied, sample sizeswere large, and the shrinkage parameter ofL1 penalizationwas tuned).With regard
to predictive performance, the difference between CARS and Cox scores became largest when marker correlations were
high. In these situations, the decorrelation of the markers, which is the key feature of CARS scores, had a particularly
strong effect on the predictive performance of the multivariable models. Conversely, screening with Cox scores, which
ignores the correlations betweenmarkers, could not discriminate between noise and influential variables in low and high
covariate correlation settings, thereby degrading predictive performance. Since IPC-weighted estimators tend to have a
high variance when censoring rates are high, we also evaluated the proposed estimators in scenarios with censoring rates
as high as 75%. Even in these extreme cases, CARS-based screening did not result in a systematically worse performance
than Cox-based screening.
It should be emphasized that CARS scores are based on the theoretical framework of parametric AFTmodels. In future
research, it will therefore be necessary to further investigate the properties of the CARS score approach in situationswhere
the conditional survival times do not follow an AFTmodel. In particular, it should be investigated whether it is possible to
extend our framework to semiparametric and/or nonlinear regression and different censoringmechanisms. Furthermore,
our simulation study did not contain a comparison of the CARS approach to other penalized regression approaches, such
as the Elastic Net12 or adaptive lasso,38 and the effect of hyperparameter tuning in penalized Cox regression was only
partially investigated. The censoring distribution influences the estimation of IPC weights, and their impact on CARS
performance (eg, in the case of nonlognormal censoring distributions or misspecification of the conditional censoring
model) will need further analysis. Evaluating the effect of different distributional assumptions on the covariates will be
another topic for future research.
5 SOFTWARE
CARS scores are implemented in R22 and published as add-on package carSurv (Version 1.0.0), which is available from
CRAN. Other packages used in this article include survival (Version 2.41-3),39 fdrtool (Version 1.2.15),40 survAUC (Version
1.0-5),41 ggplot2 (Version 2.2.1),42 mvnfast,43 PRROC (Version 1.3),44 and glmnet (Version 2.0-13).21
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